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Background: The clinical development of antimicrobial peptides (AMPs) is currently under evaluation to combat
the rapid increase in MDR bacterial pathogens. However, many AMPs closely resemble components of the human
innate immune system and the ramifications of prolonged bacterial exposure to AMPs are not fully understood.
Objectives: We show that in vitro serial passage of a clinical USA300 MRSA strain in a host-mimicking environ-
ment containing host-derived AMPs results in the selection of stable AMP resistance.
Methods: Serial passage experiments were conducted using steadily increasing concentrations of LL-37, PR-39 or
wheat germ histones. WGS and proteomic analysis by MS were used to identify the molecular mechanism asso-
ciated with increased tolerance of AMPs. AMP-resistant mutants were characterized bymeasuring in vitro fitness,
AMP and antibiotic susceptibility, and virulence in a mouse model of sepsis.
Results: AMP-resistant Staphylococcus aureus mutants often displayed little to no fitness cost and caused inva-
sive disease in mice. Further, this phenotype coincided with diminished susceptibility to both clinically prescribed
antibiotics and human defence peptides.
Conclusions: These findings suggest that therapeutic use of AMPs could select for virulent mutants with cross-
resistance to human innate immunity as well as antibiotic therapy. Thus, therapeutic use of AMPs and the impli-
cations of cross-resistance need to be carefully monitored and evaluated.
Introduction
Antibiotic resistance is one of themost urgent threats facingmod-
ern medicine. Many pathogens are acquiring resistance mechan-
isms at an alarming rate making options for treatment limited.1
Antimicrobial peptides (AMPs) are currently under evaluation as
a therapeutic solution to treat MDR pathogens.2,3 AMPs are a
diverse class of small, typically cationic peptides, which display
broad-spectrum bactericidal activity. All kingdoms of life (bac-
teria, archaea and eukaryotes)4 produce AMPs as defence
mechanisms to protect against viral, bacterial, protozoan and
fungal infections. The antibacterial activity of AMPs can be direct
by pore formation, which occurs following the interaction of posi-
tively charged, amphipathic AMPs with negatively charged bacter-
ial cell wall components such as LPS in Gram-negative and
teichoic acids (TA) in Gram-positive bacteria.5 AMPs have also
displayed bactericidal effects following translocation across the
cell wall followed by inhibition of essential cellular processes.6
As a result of this broad-spectrum bactericidal activity, at least
10 AMPs are in various stages of clinical development, the major-
ity of which are indicated for topical use.7 Several of these AMPs
are derivatives of components of the human innate immune sys-
tem. OP-145 (also known as P60.4Ac8), derived from the human
LL-37 defence peptide, is currently in phase 2 clinical trials to treat
chronic bacterial middle ear infections.9 LL-37 is the only human
cathelicidin AMP, is a key component of the human innate
immune system and serves as a first line of defence against
many bacterial pathogens.10,11 The human-derived lactoferrin
1-11 (hLF1–11) is the only AMP in clinical trials indicated for intra-
venous administration to treat life-threatening infections in stem
cell transplantation patients.12 Although no human-derived AMPs
have been FDA approved, routine administration of such AMPs
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would result in prolonged bacterial exposure ultimately selecting
for resistant mutants.13–15
Resistance development to AMPs was initially thought to be
unlikely due to the fact that these peptides kill bacteria rapidly
and typically have multiple cellular targets.16 However, it has
become increasingly evident that bacteria are able to evade
AMP killing through a variety of mechanisms including cell sur-
face modifications, external sequestering of AMPs, efflux, pro-
teolytic degradation and even by down-regulation of host AMP
production (reviewed in detail by Nizet17). These modifications
are often reversible (not stable) and only expressed under spe-
cific environmental conditions to enable bacterial pathogens to
evade AMP killing during brief AMP exposure in a host. However,
the mechanisms of stable resistance to AMPs are much less
understood. Several recent studies have shown that serial pas-
sage of bacterial pathogens in the presence of AMPs selects
for stably acquired resistance, which typically occurred at a sub-
stantial fitness cost to the bacterium.13–15,18 These studies sup-
port the notion that AMP resistance can be acquired in bacteria
to yield cross-resistant pathogens. However, AMP exposure was
performed in rich medium conditions that do not accurately
reflect a natural environment in which AMPs would be encoun-
tered. The influence that the host environment may have on
the development of stable AMP resistance has not been
characterized.
The purpose of this study was to evaluate the consequences of
prolonged AMP exposure under conditions more similar to what
would occur if AMPs were used therapeutically. The pathogen
we selected for our studies is one of the largest burdens on mod-
ern medicine, MRSA.19,20 This opportunistic pathogen is often
associated with multidrug resistance, which greatly increases
morbidity, mortality and hospital-associated costs.21 With limited
therapeutic options for XDR isolates, clinical use of AMPs to treat
MRSA infections has been proposed.7 However, with little informa-
tion available about the development of resistance to these
agents, the ramifications of widespread clinical use are largely
unknown. Here, we describe an evolution experiment conducted
in mammalian ionic environment medium (MIEM) in which a
human MRSA USA300 isolate was serially passaged in the pres-
ence of three different AMPs derived from humans, pigs and
plants.
Materials and methods
Bacterial strains, growth conditions and peptides
Bacterial strains used in this study are derivatives of the highly character-
ized community-associated MRSA USA300 strain isolated from the Los
Angeles County jail (LAC)22 cured of several small plasmids to yield strain
JE2, which has been described previously23 (termed DA28823 in our col-
lection). Insertional mutations were obtained from the Nebraska
Transposon Mutant Library.24,25 The primary growth medium used in this
study is a MIEM as described by Dorschner et al.26 made without NaCl and
adjusted to pH 7.4. Other bacterial growthmedia conditions include tryptic
soy broth/agar (TSB/A) for routine culturing, Lysogeny broth (LB) for in vitro
fitness assays andMueller–Hinton II (cation-adjusted) broth/agar for anti-
biotic susceptibility testing. All strains were grown at 378C. Dilutions and
bacterial cell washes were performed using sterile PBS (13 mM phosphate
with 137 mM NaCl at pH 7.4). For haemolysis assessments, bacterial
strains were streaked on TSA plates containing 5% v/v veal blood and incu-
bated for 24 h. AMPs were obtained from Innovagen AB (Lund, Sweden)
with the exception of a mixture of wheat germ histones (referred to as
WGH), which were a kind gift from Lars-Olof Hede´n (Lund University,
Sweden) and isolated as described.27 CNY100HL, a modified AMP derived
from the human C3 complement peptide CNY21,28 was also obtained
from Innovagen. Amino acid sequences of all peptides used in this study
are listed in Table S1 (available as Supplementary data at JAC Online).
Serial passage experiment with AMPs
The serial passage experiment was done with WT MRSA JE2 (DA28823).
The experiment was initiated at a peptide concentration equal to a growth
reduction of 30% for the DA28823 strain with the respective peptide, as
measured in a Bioscreen C reader (Oy Growth Curves AB Ltd, Finland)
with MIEM. The following concentrations of peptides were used as starting
points for the serial passage experiment: 0.75 mg/L of PR-39, 50 LL-37,
25 mg/L WGH and a combination of 6.25 mg/L WGH with 12.5 mg/L
LL-37. WT MRSA JE2 was serially passaged without peptide as a
media-adaptation control. The experiment was initiated by inoculating
eight linages of 100 mL of MIEM (with or without peptide) with 1 mL from
eight independent overnight cultures (from eight single colonies) for each
peptide treatment (or control without peptide) in a 96-well plate (Thermo
Fisher Scientific Nunc A7S, Roskilde, Denmark). The cell cultures were pas-
saged (1 mL in 100 mL freshmediumwith or without peptide) every day for
3–4 days with the initial peptide concentration. On the fourth or fifth day
the peptide concentration was increased 50% and the cell cultures where
serial passaged for another 3–4 days. In the case of poor cell growth the
cell volume transferred was either increased from 1 to 2–5 mL or the con-
centration of peptide was reduced 50% to continue passage in the previ-
ous concentration. If no growth was observed the culture was
re-inoculated from the previous day (each daily plate was saved at
2808C). These steps were repeated until the initial concentration of pep-
tidewas increased 10 times for LL-37 (500 mg/L) andWGH (250 mg/L), 12
times for the combination treatment of WGH/LL-37 (75 and 150 mg/L)
and 23 times for PR-39 (17 mg/L). At various timepoints throughout the
cycling, single colonies were isolated on LB agar from two cell lineages
per peptide, which were then whole-genome sequenced. Four control
populations passaged in MIEM without peptide were collected at the ter-
mination of the experiment as media-adapted controls.
MS analysis
The Proteomics Core Facility at Sahlgrenska Academy (Gothenburg
University) performed relative quantification of peptides. All proteomics
analyses were performed with two biological replicates of each strain.
Peptide levels for each strain are normalized on a protein median of the
WT MRSA JE2 (DA28823) replicates. A detailed description of the MS ana-
lysis is available as Supplementary data at JAC Online. All proteomics fold
change data and statistical analysis are also available as Supplementary
data at JAC Online. The MS proteomics data have been deposited to the
ProteomeXchange Consortium via the PRIDE29 partner repository with
the dataset identifier PXD004036.
Antimicrobial susceptibility assays
MIC determination
The MIC was determined using the broth microdilution method30,31 for
AMPs and by Etest for antibiotics. In both cases, the MIC was interpreted
as the lowest concentration at which no bacterial growth was observed.
Values given are the consensus MIC derived from at least two independent
determinations.
Microdilution MIC measurements for AMPs were performed using the
broth microdilution method in MIEM using 96-well plates (round bottom;
Kubicek-Sutherland et al.
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Nunc A/S). A total volume of 100 mL with a bacterial inoculum of
5×105 cfu/mL was incubated with various dilutions of peptides at 378C
for 18–20 h without shaking.
Etest WT MRSA JE2 (DA28823) and mutants strains were grown over-
night shaking at 378C in Mueller–Hinton II broth and then diluted to
108 cfu/mL in Mueller–Hinton II broth and distributed on Mueller–
Hinton II agar using a sterile cotton swab according to manufacturer’s
instructions. An Etest strip (bioMe´rieux, Marcy-l′E´toile, France) was applied
to the plate and then incubated at 378C for 18–20 h.
Bacterial cell survival assays
Bacterial strains were grown overnight shaking at 378C in TSB.
LL-37 Stationary phase cells were washed once and re-suspended in
10 mM sodium phosphate buffer at pH 7.4 (termed NaPB). Cells were sub-
sequently diluted in NaPB to 5×105 cfu/mL, combined with 3.3 mg/L
LL-37 in a final volume of 100 mL and incubated in 96-well plates in a
sealed and humidified container shaking at 378C for 2 h. Bacteriawere pla-
ted for cfu on TSA. Following overnight incubation at 378C, viable cells were
enumerated and percentage cell survival was calculated as cfuwith peptide/
cfuno peptide×100 at 2 h post-peptide exposure; values given are the
mean+SEM derived from at least three independent determinations.
Human defensins Exponential phase cells were obtained by diluting
overnight grown cells 1:100 in pre-warmed TSB and shaking at 378C for
2 h. Bacterial cells were washed once and re-suspended in NaPB. Cells
were subsequently diluted further in NaPB to 0.6924.7×104 cfu/mL, com-
bined with 1 mM (hBD3) or 10 mM (all others) of peptide in a final volume of
100 mL and incubated in 96-well plates in a sealed and humidified con-
tainer shaking at 378C for 2 h. Bacteria were plated and percentage cell
survival was calculated as for LL-37.
Assessment of membrane potential using flow cytometry
Differences in membrane potential between the strains were estimated
using a flow cytometry assay based on the BacLight Bacterial Membrane
Potential Kit according to the manufacturer (Life Technologiesw, cat. no.
B34950). Briefly, bacterial strains were grown overnight shaking at 378C
in TSB. Fifty mL of cells from each overnight culture was inoculated into
10 mL of TSB in 100 mL Erlenmeyer flasks and grown with shaking at
378C to an OD600 of 0.2. Then 15 mL of culture was transferred to 1 mL of
PBS and 10 mL of fluorescent membrane potential indicator dye, DiOC2(3)
was added. Cells were stained for 30 min at room temperature followed by
analysis on a BD Biosciences Accuri C6 flow cytometer (Becton, Dickinson
and Company), with emission filters suitable for detecting red and green
fluorescence. Fifty-thousand events were recorded at a forward scatter
threshold of 15000 and medium flow rate. Gating of stained cell popula-
tion and analysis of flow cytometry data were performed in CFloww
(Becton, Dickinson and Company). As an indicator of membrane potential,
the ratio of red to green fluorescence intensity was calculated. The assay
was verified using the protonophore CCCP and two strains derived from the
Nebraska Transposon Mutant Library25 that display reduced membrane
potential (DmenD, NE1345 and DhemB, NE184532).
Fitness measurements
At least four independent overnight cultures of each bacterial strain were
grown overnight in each of three different medium conditions: MIEM, TSB
or LB. Cells were diluted 1:1000 in the same medium as overnight growth
and 300 mLwas transferred into BioscreenC plates. Growth of the samples
was monitored at 378Cwith shaking for 16–20 h in a BioscreenC Analyzer
(Oy Growth Curves AB Ltd) with OD600 measurements taken every 4 min.
Calculations of maximum growth rate were based on OD600 values where
growth was observed to be exponential. Relative growth rates were calcu-
lated as generation timeWT/generation timemutant. Values given are the
mean+SEM derived from at least four independent determinations per-
formed in technical triplicates.
Carotenoid pigment extraction
Bacterial strains were grown overnight shaking at 378C in TSB for 24 h.
Methanol extraction of carotenoid was performed as previously
described33 with the modification that 750 mL of the culture was har-
vested by centrifugation and cells were suspended in 500 mL of methanol.
OD465 was measured with a spectrophotometer (GENESYS 10vis; Thermo
Scientific). Values presented are the mean+SEM derived from three inde-
pendent determinations.
Ethics
The Uppsala Animal Experiments Ethics Review Board in Uppsala, Sweden
approved all mouse protocols undertaken in this study under reference no.
154/14.
Mouse infections
Female BALB/c mice (6–8 weeks old) were used in all virulence studies
(Charles River Laboratories, distributed by Scanbur). A single colony of
each Staphylococcus aureus strain was grown overnight in TSB, then
diluted 1:100 in pre-warmed TSB and incubated shaking at 378C for 2 h
to achieve exponential phase growth. Cells were pelleted, washed once
in and re-suspended in PBS (13 mM phosphate with 137 mM NaCl at pH
7.4). Female BALB/c mice were administered 100 mL containing 0.5–
2×107 cfu via the intraperitoneal route. Three to four mice were used
per bacterial strain. Eight hours post-infection, mice were humanely sacri-
ficed by cervical dislocation, bacterial cells were recovered from the spleen,
liver and kidney of acutely infected animals and enumerated by direct col-
ony count following plating on TSA with overnight incubation at 378C.
Values given are normalized per gram of tissue (cfu/g).
Statistical analyses
General
Data were analysed as mean+SEM unless otherwise stated. Raw data
(membrane potential, relative fitness and carotenoid pigment) or log-
transformed data (bacterial survival) were analysed using one-way ana-
lysis of variance (ANOVA) with Fisher’s least significant difference test
used for post hoc analysis to determine statistical significance relative to
WT. Bacterial viability counts (cfu/g in tissue) were analysed relative to WT
(DA28823) using the Mann–Whitney U-test. For all statistical analyses of
P,0.05, values were considered significant and the degrees of statistical
significance are presented as ***P,0.001, **P,0.01 or *P,0.05.
Proteomics
We used the relative fold change in protein abundance (determined as
described in the MS analysis section) to calculate the mean of the bio-
logical duplicates for each strain. These average fold change values were
subject to a log transformation and, to adjust for sample variation, we
standardized the values over each strain. We then performed t-tests
between the WTs and the mutants to identify differentially expressed
accessions. The corresponding P values were corrected for multiple testing
using the Benjamini–Hochberg method to control for false discovery rate.
Since no accessions had a false discovery rate ,0.05 we selected the
Selection of resistance to defence peptides in S. aureus
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accessions with an unadjusted P,0.05 to explore pathways and clusters.
We used DAVID Bioinformatics Resources34,35 to find possible pathways for
our dataset and the GENE-E package in R36 to create heatmaps.
Results and discussion
Prolonged AMP exposure results in a stable AMP-resistant
phenotype
To assess the ability of S. aureus to become stably resistant to
AMPs, the community-associated MRSA USA300 LAC JE2 strain
was serially passaged in steadily increasing concentrations of
three different host-derived AMPs. The peptides used for selection
were the human cathelicidin peptide LL-37,2 a mixture of histones
and histone peptides derived from wheat germ (WGH) shown pre-
viously to have antimicrobial properties,37 and awell-characterized
cathelicidin defence peptide PR-39 derived frompigs.38 These three
peptideswere chosen to represent various AMP structures and host
species. Experimental evolution was conducted using MIEM
to simulate a mammalian epithelial environment.26 Seven
AMP-resistant single colony isolates that were derived from inde-
pendently passaged lineages were selected for further analysis.
Stable resistance evolved rapidly within as few as 168 genera-
tions. Themutants isolated displayed increased resistance of up to
16-fold using broth microdilution to determine the MIC of peptide
in MIEM (Table 1). Cross-resistance was also observed for all of the
mutants isolated when tested against peptides other than that
were used in serial passage. We also tested susceptibility to a
modified human C3 complement CNY21 derivative termed
CNY100HL28 and found that all mutants also displayed a slight
reduction in susceptibility to this human complement peptide,
another component of the innate immune system. The control
strains passaged in MIEM without peptide (media-adapted)
retained WT susceptibility to all peptides tested.
The solubility limit of LL-37 in MIEM (550 mg/L) hindered
determination of resistance levels by MIC; therefore, the full
extent of LL-37 resistance was assessed using time–kill assays
(Figure 1a). Two mutants passaged with LL-37 displayed a
15-fold increase in LL-37 resistance, which was associated with
a reduced membrane potential compared with WT (Figure 1b).
This parallels the observation that small-colony variant (SCV)
S. aureus, which are known to have severely defective membrane
potential, display reduced susceptibility to human AMPs.39 To
determine whether high-level resistance coincided with a growth
defect, as is seen with SCVs, we determined the fitness cost of
AMP resistance in MIEM, TSB and LB conditions relative to the
WT strain (DA28823). A growth defect was observed for all
AMP-resistant mutants in both rich medium conditions, TSB and
LB (Figure 1c and d). However, in MIEM conditions all
AMP-resistant mutants grew significantly faster than the non-
passaged WT strain (Figure 1e). These results indicate that high-
level AMP resistance can coincide with adaptation to growth in
mammalian environmental medium conditions and thereby
occur in the absence of a fitness cost.
Reduced AMP uptake results in stable AMP resistance
in S. aureus
Bacteria are able to resist the killing of AMPs through membrane
modifications (reducing the net negative charge), active efflux,
proteolytic degradation and reduced AMP uptake. To identify the
mechanism by which all seven S. aureus mutants convey a stable
AMP-resistant phenotype in the absence of selective pressure,
each mutant was subject to both whole-proteome analysis by
MS (2000 proteins) and WGS and compared with the WT,
AMP-susceptible parental strain (DA28823).
No sequence alterations were found in common S. aureus AMP
resistance determinants (dltABC, mprF, graRS, qacA; Table S2).40
Three (of seven) mutants displayed increased DltB or DltC expres-
sion (Figure 2a); however, the other factors remained unchanged
or displayed reduced expression in all sevenmutants. Instead, pro-
tein analysis revealed two major patterns that all seven
AMP-resistant mutants displayed but were not observed in the
AMP-susceptible WT (DA28823) or media-adapted control strain
(cycled without peptide, DA30560), i.e. (i) reduced haem/mena-
quinone biosynthesis, and (ii) reduced expression of various
transporters.
Table 1. AMP-resistant S. aureus display cross-resistance to various AMPs
Strain no. Passaged with Approximate no. of generationsa
MIC (mg/L)b
LL-37 WGH PR-39 CNY100HLc
DA28823 WT, no passage none 192 16 4 24
DA30560 no peptide 322 192 16 4 24
DA29677 LL-37 189 .512 64 4 48
DA29680 LL-37 189 .512 128 8 32
DA30557 WGH 322 .512 192 12 48
DA30559 WGH 322 .512 256 12 32
DA36424 LL-37 and WGH 210 .512 192 12 32
DA35920 PR-39 168 .512 128 8 32
DA37296 PR-39 168 .512 96 8 32
aCalculated based on number of generations achieved in MIEM without peptide.
bMIC was determined in MIEM using the broth microdilution method.
cCNY100HL is a modified AMP derived from the human C3 complement peptide CNY21.28
Kubicek-Sutherland et al.
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Defects in electron transport have been previously associated
with reduced uptake of AMPs and consequently AMP resistance in
S. aureus mutants displaying a SCV phenotype.41 All seven
AMP-resistant mutants displayed slight reductions in the expres-
sion of components in the menaquinone or haem biosynthesis
pathways required for synthesizing electron transport chain com-
ponents (Figure 2b). An electrochemical gradient is necessary for
the import of positively chargedmolecules such as AMPs and ami-
noglycosides. Therefore, reduced electron transport is a mechan-
ism by which stable AMP resistance can be achieved in S. aureus.
None of the seven AMP-resistant mutants display genetic
mutations (i.e. haemin/menadione biosynthesis, cytochrome c
assembly, thyA) or growth defects commonly associated with
an SCV phenotype. With a complete interruption of the electron
transport chain, neither oxygen nor nitrate would be utilized as
electron acceptors and there would be an up-regulation of anaer-
obic respiration. Contrarily, these AMP-resistant mutants display a
reduced expression of fermentation enzymes (ldh1 and ldh2) and
anaerobic metabolism (pflA, pflB) while expression of glycolysis
and citric acid cycle components remained unaltered (tpiA,
gapdh, acnA, sucC and sdhC). Nitrate respiration (narGHIJ) was
also increased in six of seven AMP-resistant mutants (Figure 2c).
Therefore, there does not appear to be a complete disruption in
electron transport chain in these AMP-resistant mutants.
ATP-binding cassette (ABC) transporters actively transport vari-
ous substrates across cell membranes. In bacteria, ABC transpor-
ters are involved in many processes including nutrient acquisition,
environmental sensing, virulence (adhesion and protein secretion)
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Figure 1. AMP resistance in S. aureus can evolvewithout a fitness cost. (a) Extent of LL-37 resistancewas determined by calculating percentage bacterial
survival after LL-37 exposure. Fold changes overWT (DA28823) are indicated above each bar. (b) Differences inmembrane potential are presented as the
ratio of red/green fluorescence intensity following incubation with the fluorescent membrane potential indicator dye DiOC2(3). Assay was verified using
the protonophore CCCP and two strains derived from the Nebraska Transposon Mutant Library that display reduced membrane potential (DmenD,
NE1345 and DhemB, NE184532). Fitness was determined in (c) TSB, (d) LB or (e) MIEM growth conditions. Relative fitness is presented as the
maximum exponential generation time relative to WT with the broken line representing the relative WT growth rate. All values given are the
mean+SEM derived from at least three independent determinations. Relative fitness assays were also performed in technical triplicate. Statistical
significance relative to WT (DA28823) was determined by one-way ANOVA with Fisher’s least significant difference test used for post hoc analysis
(***P,0.001, **P,0.01 or *P,0.05). All relative fitness values were statistically significant with P,0.001.
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and antimicrobial resistance (efflux and influx).42 All seven
AMP-resistant S. aureus mutants displayed reduced expression
of ABC transporters involved in transferring peptides (ddpA, gsiA,
oppA, hypothetical protein Q2FZR6), iron (fecB, hypothetical pro-
tein QRFZM4) and amino acids (metN1, metN2) across the bacter-
ial membrane (Figure 2d). Reducing cellular uptake of peptides is a
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Figure 2. Stable AMP resistance is conferred by reduced AMP uptake. Heatmaps of selected protein expression profiles grouped into categories based on
their biological roles: (a) AMP resistance determinants; (b) electron transport chain; (c) metabolism; (d) transporters; and (e) virulence factors. S. aureus
strains (AMP-resistant mutants or WT) are indicated above each column and protein expression is shown in rows. Proteomics analysis was performed
using MS in bacterial cells derived from exponential growth in TSB medium in the absence of AMP selection as described in the Materials and methods
section. Each column represents the average fold change calculated relative toWT (DA28823) for the indicated protein. All expression experiments were
performed with two biological replicates. Changes in protein expression levels are represented in colour: yellow indicates increased protein levels and
blue indicates decreased protein levels relative to WT. Data are available via ProteomeXchange with identifier PXD004036.
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direct mechanism by which AMP resistance can be achieved in
S. aureus to convey a stable cross-protective phenotype against
a variety of AMPs. Reduced iron uptake can indirectly confer AMP
resistance by resulting in a disruption of many cellular processes
including assembly of the electron transport chain.43
The genetic basis of reduced AMP uptake in AMP-resistant
S. aureus mutants appears to be multifactorial. Each mutant
was found to contain between one and three mutations relative
to the sequence of our WT JE2 strain, the vast majority of which
were single amino acid substitutions (Table S2). Mutations were
identified in a variety of cellular pathways including global regula-
tors (srrA, srrB, walK, rpoB, phoR), nucleotide synthesis/signalling
(gmk, guaA), nutrient uptake (ptsI, trkA) and virulence factors
(cspA, ebh, mazF). Protein expression profiles indicated a repres-
sion of staphylococcal respiratory response (srrAB, also known
as srhSR) regulated genes in all seven AMP-resistant mutants of
S. aureus (Figure 2b). SrrAB is a two-component regulatory system
involved in sensing and maintaining the electron transport chain
by activating cytochrome and quinol-oxidase assembly (ctaB,
cydAB, qoxABCD) and haem biosynthesis (hemACDX) in response
to impaired electron flow.44
Reconstruction of these mutations singly in a clean back-
ground failed due to the inherent difficulty in S. aureus allelic
replacement and lack of an easily selectable phenotype for trans-
duction (i.e. AMP activity is highly dependent on medium condi-
tions and cost-prohibitive). Insertional knockouts of genes that
were available from the Nebraska Transposon Mutant Library24,25
did not display AMP resistance (data not shown). Therefore, the
individual contribution of each mutation towards the AMP resist-
ance phenotype and/or adaptation to growth in MIEM is unknown.
Media adaptation in control versus AMP-resistant
populations
Mutations were identified in three of seven AMP-resistantmutants
in the uncharacterized gene SAUSA300_1112 (predicted to
encode a phosphatase 2C domain-containing protein). Two of
these mutations result in inactivation via frameshift or introduc-
tion of an early stop codon. However, an insertional knockout
mutant of SAUSA300_1112 from the Nebraska Transposon
Mutant Library does not display AMP resistance (data not
shown) indicating a likely role of this mutation in adaptation to
growth in MIEM.
Interestingly, noneof the fourmedia-adapted controls passaged
without peptide contained mutations in SAUSA300_1112
(Table S3). The four independent control populations passaged in
MIEM without peptide displayed a very different mutational profile.
In fact, only one AMP-resistant mutant (DA30557) contained a
mutation in a gene that was identified in the control populations
and could be attributed to MIEM adaptation (SAUSA300_2326, a
transcription regulatory protein). Instead, all four control popula-
tions contained mutations in either the SaeRS and/or ArlRS two-
component virulence regulators, the majority of which included
either a frame shift or early stop codon indicating an inactivation
of these global virulence regulators. None of the AMP-resistant
mutants displayed mutations in either of these virulence determi-
nants. These findings indicate that the selective pressure imposed
by the presence of AMPs results in alternate pathways for adapta-
tion in MIEM conditions.
AMP resistance reduces susceptibility to clinically
prescribed antibiotics
The impact of AMP resistance on the susceptibility of S. aureus to
antibiotics was tested against 15 drugs representing five classes
indicated for the treatment of MRSA infections (Table 2). MICs
were determined using Mueller–Hinton medium conditions,
which are the clinically accepted standards for determination of
antimicrobial susceptibility. All seven AMP-resistant mutants dis-
played diminished susceptibility to teicoplanin, a glycopeptide
antibiotic structurally related to vancomycin, yet all seven
mutants displayed little to no change in susceptibility to vanco-
mycin. All seven AMP-resistant mutants were also less susceptible
to daptomycin, a lipopeptide antibiotic. Cross-resistance between
daptomycin and human defence peptides in MRSA has been pre-
viously observed.45 DA29677 (passagedwith LL-37) and DA35920
(passaged with PR-39) displayed an 8- and 10-fold increase in
daptomycin MIC, respectively, which is approaching clinical resist-
ance (.1 mg/L) according to breakpoints defined by EUCAST. Four
of seven mutants also displayed reduced susceptibility to genta-
micin, a protein synthesis inhibitor, with an 8-fold increase in MIC
for DA30557 (passaged with WGH), which is also at the clinical
resistance level (.1 mg/L, EUCAST). Additionally, AMP-resistant
S. aureus also displayed diminished susceptibility to tetracycline
(six of sevenmutants), polymyxin B (three of seven), erythromycin
(two of seven) and tigecycline (two of seven). These results indi-
cate that AMP-resistant S. aureus are less susceptible to clinically
prescribed antibiotics from three of the five drug classes tested,
which will further limit effective therapeutic options to treat
these infections.
AMP-resistant S. aureus maintain virulence
Antimicrobial resistance in bacterial pathogens has often been
associated with a fitness cost and/or alterations in virulence cap-
acity.43,46,47 Virulence factors are required for bacterial survival in
a host. In S. aureus, the expression of cell wall adhesins occurs
during initial colonization while the production of toxins occurs
later during dissemination in tissue.48 Expression of virulence fac-
tors in S. aureus is depending on environment and growth phase
under the control ofmanyoften overlapping global regulatory sys-
tems (i.e. agrAC, sarA, srrAB, saeRS, arlRS, lytRS). Protein expression
profiles of AMP-resistant S. aureus mutants reveal an increase in
colonization-related regulators and virulence factors including
immunoglobulin G-binding protein (spa), autolysin (lytM) and
fibronectin-binding protein A (fnbA) (Figure 2e).
With an increase in colonization factors, we determined
whether AMP-resistant S. aureus mutants were capable of expres-
sing virulence factors required for later stages of infection.
Haemolysis is considered to be one of the major factors contrib-
uting to the transition of S. aureus from a commensal organism to
an invasive pathogen.49 To evaluate the haemolytic activity of
AMP-resistant S. aureus, we isolated the mutant and WT strains
on veal blood agar plates (Figure 3a). The WT displayed both a-
and b-haemolysis on veal blood, which are indicated by green
and yellow discoloration, respectively. AMP-resistant mutant
DA29677 (passaged with LL-37) displayed greatly reduced
haemolytic activity, which was confirmed by proteomic analysis
(Figure 2e). Four of seven mutants displayed moderate to high-
level b-haemolytic activity similar to WT; however, a reduction
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Table 2. AMP-resistant S. aureus display increased resistance to clinically prescribed antibiotics
Strain no. Cycled with
Peptidoglycan
synthesis
inhibitors/clinical
breakpointa
(mg/L)
Detergent-like
peptide
antibiotics/clinical
breakpointa
(mg/L) Protein synthesis inhibitors/clinical breakpointa (mg/L)
Folate synthesis
inhibitors/clinical
breakpointa (mg/L)
RNA synthesis
inhibitor/clinical
breakpointa (mg/L)
VAN TEC CFT DAP PMB GEN CHL CLI ERY LZD TGC TET DOX SXT RIF
R.2 R.2 R.1 R.1 ND R.1 R.8 R.0.5 R.2 R.4 R.0.5 R.2 R.2 R.4 R.0.5
MIC (mg/L)b
DA28823 WT 1.5 0.5 0.25 0.094 96 0.125 4 0.094 0.19 2 0.094 0.094 0.19 0.094 0.012
DA30560 no peptide 1.5 0.5 0.25 0.094 64 0.125 4 0.094 0.19 2 0.094 0.094 0.19 0.094 0.012
DA29677 LL-37 2 1.5 0.19 0.75 96 0.094 6 0.047 0.19 1.5 0.094 0.19 0.125 0.047 0.008
DA29680 LL-37 2 2 0.25 0.19 96 0.094 4 0.094 0.19 1.5 0.19 0.25 0.094 0.064 0.012
DA30557 WGH 2 1 0.38 0.19 192 1 4 0.064 0.125 2 0.094 0.25 0.094 0.064 0.012
DA30559 WGH 1.5 1.5 0.38 0.19 192 0.38 4 0.064 0.125 1 0.094 0.19 0.125 0.094 0.016
DA36424 LL-37 and WGH 2 1.5 0.38 0.38 96 0.19 4 0.125 0.25 2 0.19 0.25 0.25 0.094 0.012
DA35920 PR-39 2 2 0.19 1 128 0.25 3 0.094 0.38 1 0.125 0.125 0.094 0.094 0.016
DA37296 PR-39 2 1.5 0.25 0.38 384 0.5 6 0.125 0.38 2 0.125 0.19 0.125 0.064 0.008
VAN, vancomycin; TEC, teicoplanin; CFT, ceftaroline; DAP, daptomycin; PMB, polymyxin B; GEN, gentamicin; CHL, chloramphenicol; CLI, clindamycin; ERY, erythromycin; LZD, linezolid; TET,
tetracycline; TGC, tigecycline; DOX, doxycycline; SXT, trimethoprim/sulfamethoxazole; RIF, rifampicin.
Light grey, 2–5-fold MIC increase; dark grey, .5-fold MIC increase.
aDerived from EUCAST Clinical Breakpoint Table v. 5.0, valid from 1 January 2015 for Staphylococcus spp. (R, resistant; ND, no value determined).
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in a-haemolysis was observed. The PR-39 passaged mutant
DA37296 displayed both a- and b-haemolytic activity similar to
the virulent WT strain (DA28823) indicating that AMP resistance
can be achieved in the absence of a defect in haemolysis.
Another virulence determinant of S. aureus is its golden pig-
mentation. The production of yellow carotenoid pigment has
been shown to promote virulence by protecting the bacterium
from phagocyte killing.50 Levels of carotenoid pigment production
were assessed using methanol extraction (Figure 3b) and notably
the PR-39 passaged mutant DA35920 displayed a marked eleva-
tion in carotenoid pigment production. An increase in carotenoid
pigment production in S. aureus has previously been associated
with a thickening of the bacterial cell wall resulting in resistance
to antibiotics targeting the cell wall,33 which corresponds with
the daptomycin and teicoplanin resistance found in this
AMP-resistant mutant (Table 2). Together, these results indicate
that AMP resistance in S. aureus can result in enhanced patho-
genic properties.
Previous studies have shown that stable AMP resistance muta-
tions can result in attenuation of S. aureus in an invasive disease
model.51,52 To determine whether AMP-resistant S. aureus was
capable of causing invasive disease we used a mouse model of
sepsis. Mice were infected intraperitoneally with 0.5–2×107 cfu
and the ability of S. aureus AMP-resistant mutants to disseminate
invasively was assessed at 8 h post-infection. Bacterial coloniza-
tion of the spleen (Figure 3c), liver (Figure 3d) and kidney
(Figure 3e) were used as indicators of virulence capacity com-
pared with the fully virulent WT strain. Fewer AMP-resistant
S. aureus mutants were recovered from the spleen of infected
mice compared with WT for all mutants (Figure 3c). However,
all AMP-resistant mutant strains achieved similar levels of colon-
ization to WT in both the liver and kidney (Figure 3d and e),
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Figure 3. AMP-resistant S. aureus are virulent. (a) Haemolytic activity was assessed following isolation on veal blood agar. (b) Carotenoid pigment
production was assayed using methanol extraction. Values presented are the mean+SEM derived from three independent determinations and
statistical significance relative to WT was analysed using one-way ANOVA with Fisher’s least significant difference test for post hoc analysis
(***P,0.001 or *P,0.05). To assay in vivo virulence capacity, BALB/c mice were infected intraperitoneally with 0.5–2×107 cfu of S. aureus and
bacterial cells were enumerated from the (c) spleen, (d) liver and (e) kidney. Values presented are bacterial cfu counts normalized per gram of tissue
(cfu/g) from three to four mice per bacterial strain. Boxes show the median and 25th and 75th percentiles, while error bars show the minimum and
maximum values. Significant differences in bacterial colonization of AMP-resistant S. aureus strains were determined relative to WT using the Mann–
Whitney U-test (*P,0.05).
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indicating that AMP-resistant S. aureus are fully capable of dis-
seminating and causing invasive disease in mice. Thus, it is also
important to note that fitness evaluations in rich medium condi-
tions may not accurately reflect the capacity of AMP-resistant
mutants to persist in vivo.
AMP-resistant S. aureus resist killing by human defensins
In humans, the skin provides a substantial barrier for S. aureus to
cause invasive disease. Persistent S. aureus colonization of the
nasal passages occurs in 20% of healthy adults53 increasing
the risk of invasive infection in these individuals.54 The production
of AMPs in the skin, particularly in the nasal passages, plays a
major role in preventing S. aureus persistent colonization and
consequently people displaying defects in b-defensin 3 (hBD3)
production show enhanced nasal colonization of S. aureus.55 To
evaluate the capacity of AMP-resistant S. aureus to evade the
human defensins required to control colonization, we deter-
mined the susceptibility of these mutants to all 10 of the
human defensins. Highly AMP-resistant mutants displayed WT
susceptibility to the six a-defensins (Figure 4a) with one high-
level LL-37 resistant mutant (DA36424) displaying significantly
reduced survival when exposed to HNP6. In contrast, six of
seven mutants showed enhanced resistance to at least one of
the human b-defensins (Figure 4b–e). The other high-level
LL-37 resistant mutant DA29677 showed increased resistance
to hBD1, hBD2 and hBD3. These results indicate that human
innate immune peptides, including hBD3, are less capable of kill-
ing AMP-resistant S. aureus.
It is becoming increasingly evident that the interactions
between host and pathogen can greatly impact the efficacy of
clinical therapeutics and that the design of novel containment
strategies should account for these dynamics.56,57 The host–
pathogen interactions involved in the transition of S. aureus
froma commensal organism to an invasive pathogen are complex
and not yet fully characterized. It is known that host AMPs provide
a significant barrier to S. aureus colonization in humans.55 Our
results indicate that prolonged exposure to either human-, pig-
or plant-derived AMPs results in the selection of stably resistant
S. aureus mutants capable of evading host defensins. With a step-
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Figure 4. AMP-resistant mutants are less susceptible to human defensins. (a) Susceptibility to the human a-defensins was determined by calculating
percentage bacterial survival following 2 h of exposure to 10 mM peptide. Susceptibility to the human b-defensins (b) hBD1, (c) hBD2, (d) hBD3 and (e)
hBD4was determined as for a-defensins with 10 mM (hBD1, hBD2, hBD4) or 1 mM (hBD3) peptide concentrations. Limit of detection of the assay was 1%
survival. Values given are themean+SEMderived fromat least three independent determinations. Statistical significance relative toWTwas determined
by performing one-way ANOVAwith Fisher’s least significant difference test used for post hoc analysis on log-transformed data (***P,0.001, **P,0.01
or *P,0.05).
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wise selection occurring at the typical mutation rates58 in the
population sizes found in S. aureus during colonization,59 it is con-
ceivable that resistant mutants could be selected. These mutants
conveyed a resistance phenotype associated with reduced AMP
uptake, which corresponded with increased expression of colon-
ization factors. Consequently, widespread clinical usage of such
peptides as therapeutics could inadvertently enrich for bacteria
that are intrinsically resistant to a major component of the innate
immune system and more capable of colonizing a host; and as a
result, increase the fraction of the human population that is per-
sistently colonized with S. aureus.60
It is also known that individuals who are persistently colonized
with S. aureus are at a greater risk of contracting symptomatic and
invasive infections typically resulting from the same strain with
which they were colonized.54 We have shown that AMP-resistant
S. aureus is fully capable of causing invasive disease, which
would require antibiotic treatment. However, these mutants also
displayed reduced susceptibility to antibiotics, which would there-
fore limit therapeutic options to treat these infections. As a result,
administration of precious last resort drugs such as vancomycin
would provide further selection for antibiotic resistance. Clinical
resistance to antibiotics such as daptomycin are associated with
the development of a thicker cell wall, which in turn results in
enhanced resistance to host AMPs,45 potentially creating a vicious
cycle ultimately rendering S. aureus infections particularly difficult
to treat (Figure 5). These findings highlight the importance of
evaluating the development of bacterial resistance in the context
of the host environment and have important implications for pub-
lic health in the event that AMPs enter routine clinical use.
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